ArticleBiomedicines2022
Anti-Quorum Sensing Activities of Gliptins against
Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 60 citations in OpenAlex.
- Molecular Characterization of vanA and blaMolecular biology reports · 2026Article
- Suppression of Quorum Sensing and Virulence Factors by Meloxicam and Celecoxib in Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Morusin attenuates myocardial ischemia/reperfusion injury by inhibiting ferroptosis via dual activation of the Nrf2/HO-1 pathway and mTORC1-dependent GPX4 synthesis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A Cyclic Pentapeptide Inhibits AgrC as a Quorum-Sensing Quenching Agent inAntibiotics (Basel, Switzerland) · 2026Article
- Bacterial quorum-sensing systems in cell-cell communication.FEMS microbiology reviews · 2026Review
- Research Progress on Antivirulence Agents Targeting the Accessory Gene Regulator (Agr) System ofInfection and drug resistance · 2026Review
- Molecular Framework of Multidrug Resistance in Pseudomonas aeruginosa.Current microbiology · 2025Review
- Preclinical evaluation of repositioned non-antibiotic agents against Staphylococcus aureus: a network meta-analysis of survival outcomes.World journal of microbiology & biotechnology · 2025Article
- Enhanced meropenem activity and stability following load in Polyvinyl alcohol nanofiber scaffolds with sitagliptin as quorum sensing inhibitor on Pseudomonas aeruginosa.Journal of biological engineering · 2025Article
- In vitro and in vivo investigation of the antibacterial, antivirulence, and antiquorum sensing activities of β-carotene against difficult-to-treat resistant Pseudomonas aeruginosa.BMC microbiology · 2025Article
- Reviving Furosemide as a Metallo-β-Lactamase Inhibitor against MDRJournal of microbiology and biotechnology · 2025Article
- Anti-QS Strategies AgainstMicroorganisms · 2025Review
- Mastoparan-S from Sphodromantis viridis exhibits antimicrobial activity by disrupting bacterial membranes.AMB Express · 2025Article
- Targeting virulence of resistant Escherichia coli by the FDA-approved drugs sitagliptin and nitazoxanide as an alternative antimicrobial approach.Folia microbiologica · 2025Article
- Article
- DisarmingPathogens (Basel, Switzerland) · 2025Review
- Vitamin D3 potentiates antimicrobial and antibiofilm activities of streptomycin and thymoquinone against Pseudomonas aeruginosa.World journal of microbiology & biotechnology · 2025Article
- Celastrol boosts fluconazole efficacy against vaginal candidiasis: in vitro and in vivo evidence.AMB Express · 2025Article
- Quorum Sensing and its Inhibition inCurrent drug targets · 2025Review
- Unveiling the antibacterial action of ambroxol against Staphylococcus aureus bacteria: in vitro, in vivo, and in silico investigation.BMC microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of bacterial resistance to traditional antibiotics constitutes an emerging public health issue. Promising approaches have been innovated to conquer bacterial resistance, and targeting bacterial virulence is one of these approaches. Bacterial virulence mitigation offers several merits, as antivirulence agents do not affect the growth of bacteria and hence do not induce bacteria to develop resistance. In this direction, numerous drugs have been repurposed as antivirulence agents prior to their clinical use alone or in combination with traditional antibiotics. Quorum sensing (QS) plays a key role in controlling bacterial virulence. In the current study, dipeptidase inhibitor-4 (DPI-4) antidiabetic gliptins were screened for their antivirulence and anti-quorum sensing (anti-QS) activities against Gram-negative
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.